Insulet (NASDAQ: PODD), headquartered in Acton, Massachusetts, and with offices and manufacturing facilities around the world, is a global company with growing reach. We strive to bring our innovations to all who need them, wherever they are.

Insulet (NASDAQ: PODD) is an innovative medical device company improving the lives of people with diabetes and other conditions through its Omnipod delivery system.

2024年12月4日 · Insulet Corporation is an innovative medical device company based in Acton, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. Specifically, through our revolutionary Omnipod Insulin Management System, we seek to expand the use of insulin pump therapy.

Our products deliver groundbreaking innovation. Insulet was the first medical device manufacturer to develop a tubeless insulin delivery system and a mobile app that helps people manage their diabetes remotely.

2024年8月26日 · ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 ...

We have also launched the Omnipod 5 App for iPhone ® in the U.S., making Insulet the first and only company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible iPhone or Android™ phone.

2024年6月21日 · Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller.

Jan. 28, 2022- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged ...

2024年11月20日 · Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S.

Sketching the first design of Pod therapy on a napkin, he paved the way for Insulet’s Omnipod technology, a tubeless, wearable, disposable insulin Pod. From Insulet’s first iteration of Pod therapy to today’s revolutionary Omnipod 5 Automated Insulin Delivery System, our customers’ needs remain our inspiration and drive our progress.